| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
|
Medicine details |
|
| Medicine name | obinutuzumab (Gazyvaro®) |
| Formulation | intravenous infusion |
| Reference number | 1315 |
| Indication | In combination with bendamustine followed by Gazyvaro maintenance for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen. |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/05/2016 |
| NICE guidance | TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Commercial arrangement | PAS |